A Phase 1/2 interventional study of Endotracheopulmonary Instillation, Suspension in Bronchopulmonary Dysplasia, sponsored by EXO Biologics S.A.. Recruiting at 8 sites in 2 countries. Open to participants aged Up to 10 Days. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by EXO Biologics S.A. · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Bronchopulmonary Dysplasia with a site in Italy — 6 open to participants now, 8 under way, 1 of them phase 3. Bronchopulmonary Dysplasia · Italy.
Among the 16 studies in Bronchopulmonary Dysplasia with a site in Italy, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 1/2, and was the 13th registered.
363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.
Browse Bronchopulmonary Dysplasia studies →6 of the 16 studies in Bronchopulmonary Dysplasia with a site in Italy are open now. Recruiting first, the newest first:
Airway Therapeutics, Inc. · Sites in Italy, Argentina, Belgium and 7 more countries
Ages 0 min–96 hrs
Azienda USL Reggio Emilia - IRCCS · Sites in Italy
Ages up to 31 wk
Fondazione IRCCS San Gerardo dei Tintori · Sites in Italy, Austria, Netherlands and 2 more countries
Ages 5 days–9 days
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 24 wk–27 wk
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 1 hrs–24 hrs
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 57 Bronchopulmonary Dysplasia studies recruiting now, 6 (11%) set no upper age limit and 50 (88%) stop at 75 or younger; 55 take children under 18; 11 take healthy volunteers.
This study: Up to 10 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 3
First in 2008; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 265 is above the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.
Median enrollment 193 across the 12 interventional studies, 35 across the 4 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with EXO Biologics S.A. as lead sponsor.
EXO Biologics S.A. has 1 study filed under Bronchopulmonary Dysplasia — fewer than ten, so there is no comparison to draw.
3 of the studies in Bronchopulmonary Dysplasia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT06279741EXO Biologics S.A.Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants | 2027-01-31 |
| NCT07633184Azienda USL Reggio Emilia - IRCCSLung Ultrasound Score for Early Prediction of Bronchopulmonary Dysplasia in Preterm Newborns | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Bronchopulmonary Dysplasia with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in extremely premature neonates. The study population includes babies born between 23 and 28 (27 + 6 days) weeks of gestational age and body weight between 500g and 1,500 g. Thirty-six subjects will receive one or three administrations of the three doses of EXOB-001 via the endotracheal route in phase 1. In phase 2, two dosages based on the results of phase 1 will be selected and a total of 203 subjects will be randomised to receive either EXOB-001 or placebo (saline solution).
Infants will be followed up to 2 years of corrected age (end of study).
Bronchopulmonary Dysplasia (BPD) is a chronic severe multifactorial respiratory disease that affects extremely premature infants and is the most common and severe consequence of preterm birth. BPD is associated with disrupted alveolarization and microvascular development, resulting in abnormal gas exchange and lung mechanics. BPD has a multifactorial aetiology, with pre-, peri-, and postnatal mechanisms causing inflammation and injury and resulting in the disruption of the lung's development with the insurgence of an aberrant repair mechanism.
EXOB-001 consists of a population of EVs smaller than 0.22 μm in diameter, containing proteins and nucleic acids, enclosed in a double layer of phospholipids with integral and surface-bound proteins as the main components. EVs exert anti-inflammatory and immunomodulatory activity by reducing the release of proinflammatory cytokines and reducing the recruitment of immune cells in the lung. Current evidence shows that EVs can modulate macrophage phenotype, and this is relevant for BPD, because of the role macrophages have in its pathogenesis.
Two hundred sixty-five (265), 40 in phase 1 (to reach 36 evaluable subjects) + 225 in phase 2 (to reach 203 evaluable subjects), extremely preterm infants at risk of developing BPD with 23 weeks up to 28 (27 weeks+6 days) weeks of gestational age and birth weight between 500g and 1,500g and being endotracheally intubated between postnatal day 3 and day 10 receiving mechanical ventilation with FiO2 > 25%.
Phase 1 will start with cohorts with a single administration starting with a low dose up to a high dose and thereafter start the escalation of cohorts with 3 administrations starting with a low dose up to a high dose. In the case of 3 endotracheal administrations, there will be a window of 24 hours between the administrations (the maximal duration of the treatment with EXOB-001 will be 48 hours).
Phase 2 includes 2 groups with selected dosage levels and regimen of EXOB-001 based on phase 1 interim results. Subjects will be randomised (2:2:1) to receive either EXOB-001 or placebo (saline solution).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EXOB-001 will be administered via the endotracheal route in an already intubated newborn. EXOB-001 will be administered in three dose levels (low dose, medium dose and high dose) with one or three administrations.
Biological: Endotracheopulmonary Instillation, Suspension
In phase 2, active group 1 consists of administering the first (out of two) of the safest selected dose/regimen of EXOB-001 based on phase 1 interim results.
Biological: Endotracheopulmonary Instillation, Suspension
In phase 2, active group 2 consists of administering the second (out of two) of the safest selected dose/regimen of EXOB-001 based on phase 1 interim results.
Biological: Endotracheopulmonary Instillation, Suspension
In phase 2, the saline solution for infusion is used as a placebo.
Biological: Endotracheopulmonary Instillation, Suspension
The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube. The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant.
Also known as: Endotracheopulmonary instillation
Number of subjects with treatment-emergent adverse events (phase 1)
The proportion of subjects exhibiting acute and short-term safety of the intratracheal administration of EXOB-001 (single dose or multiple doses at different dose levels).
Time frame: From EXOB-001 administration up to 36 weeks post-menstrual age (PMA)
Number of subjects with BPD grade II-III incidence rate per groups (phase 2).
BPD grade II-III incidence rate per group assessed at 36 weeks PMA. The severity of BPD is assessed according to the modified NICHD severity grading (Grade I to IIIA) definition.
Time frame: 36 weeks PMA
Assessment of medium-term safety of EXOB-001 (phase 1/2)
The proportion of subjects experiencing treatment-emergent adverse events (TEAE) from EXOB-001 administration up to hospital discharge
Time frame: From EXOB-001 administration to hospital discharge (between 36 and 40 weeks PMA)
Number of subjects with dose-limiting toxicity (DLT) (phase 1)
DLT is measured as: * cardiorespiratory decompensation; * decrease in SpO2/FiO2 ratio; * stable increase in required mean airway pressure \>3 cm H2O; * death, * anaphylactic reaction. * any serious adverse reaction (SAR) considered as at least possibly related to EXOB-001 administration.
Time frame: 6 hours and 24 hours after EXOB-001 administration
Number of subjects needing for oxygen and ventilation for BPD incidence (phase 1/2)
The number of subjects needing oxygen and ventilation support.
Time frame: 28 days chronological age, 36 weeks PMA, 40 weeks PMA
Assessment of immune markers (phase 2)
To test immune markers in the tracheal aspirate fluid.
Time frame: Baseline (before EXOB-001 administration), baseline + 24 hours before EXOB-001 administration, baseline + 72 hours if the the subject is still intubated
Assessment of BPD incidence and severity (phase 1/2)
The number of cases and severity of BPD were measured according to different definitions (modified NICHD severity grading (Grade I to IIIA), Jobe and Bancalari 2001, and Isayama 2017).
Time frame: 28 days of chronological age, 36 weeks PMA and 40 weeks PMA
Safety evaluation (phase 1/2)
All adverse events (AEs) and serious adverse events (SAEs) (including case fatalities), both related and non-related.
Time frame: From enrolment to 2 years of corrected age (end of study)
Assessment of lung ultrasound score (phase 1/2)
The lung ultrasound score (LUS) aims to assess lung development in all groups by lung ultrasound at different time points. Each lung is divided into 3 areas (upper anterior, lower anterior, lateral), and each area will be evaluated by assigning a value ranging from 0 to 3 to each zone, with a consequent overall value ranging between 0 and 18 in all infants scanned on the anterior and later thorax, and also another score (called extended lung ultrasound score or eLUS) in those infants scanned posteriorly ranging between 0 and 30. The lung ultrasound scores were assigned as follows: * 0, indicates an A-pattern (defined by the presence of the only A-lines); * 1, indicates a B-pattern (defined as the presence of ≥3 well-spaced B-lines); * 2, indicates severe B pattern (defined as the presence of crowded and coalescent B lines with or without consolidations limited to the subpleural space); * 3, indicates extended consolidations.
Time frame: From baseline to 2 years of corrected age (end of study)
Number of subjects with complications of prematurity (phase 1/2)
To assess all known complications of prematurity, concomitant treatments/procedures/therapies in all groups.
Time frame: From baseline to 2 years of corrected age (end of study)
Assessment of the respiratory morbidity (phase 1/2)
To evaluate the respiratory morbidity by the Liverpool Respiratory Symptom Questionnaire in all groups at different time points. Parents are asked to consider respiratory symptoms over the last 3 months, with questions being scored on a five-point Likert scale from ''not at all'' (score 0) to ''every day'' (score 4). A score for each domain and the complete questionnaire is calculated.
Time frame: From hospital discharge to 2 years of corrected age (end of study)
Assessment of neurodevelopment (phase 1/2)
To evaluate the neurodevelopmental condition by the ASQ3 questionnaire in all groups with age-specific questionnaires at different time points. The neurodevelopment will be assessed by five domains: communication, gross motor, fine motor, problem-solving, and personal-social. Parents will fill out each item and indicate whether the baby is doing the activity regularly (10 points), sometimes (5 points), or not yet (0 points). The total score of each developmental area is compared to the area cut-offs.
Time frame: From hospital discharge to 2 years of corrected age (end of study)
Not enrolling at this site.
Not enrolling at this site.
Started Dec 2023 (actual). Primary completion is estimated for Jan 2027, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.